MitoQ and Exercise Effects on Vascular Health

Aging Clinical Trial

— MITO-STEP  

Official title:

MitoQ Supplementation for Restoring Aerobic Exercise Training Effects on Endothelial Function in Postmenopausal Women

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05686967
• Other study ID #: 22-1521
• Secondary ID: R56AG072094
• Status: Recruiting
• Phase: Early Phase 1
• Start date: January 16, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2023
• Source: University of Colorado, Denver
• Contact: Kerrie L Moreau, PhD
• Phone: 3037241914
• Email: kerrie.moreau[@]cuanschutz.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An impairment in vascular function can lead to the development of age-associated cardiovascular disease (CVD), the leading cause of death in postmenopausal women. Regular aerobic exercise (AE) benefits vascular function in older men by reducing oxidative stress, however, similar AE training improvements are diminished or absent in postmenopausal women. not using estrogen-based hormone therapy. Vascular function and oxidative stress are improved with AE training in postmenopausal women treated with E2, suggesting an essential role of E2 in vascular adaptations to AE in women. Clinical use of E2 is contraindicated for this purpose, thus establishing alternative pharmacological approaches that could be administered as a substitute for E2 to improve AE signaling for vascular benefits and reducing CVD risk in E2-deficient postmenopausal women is biomedically important. The mitochondrial-targeted antioxidant MitoQ may be an alternative to E2 for restoring AE benefits in E2-deficient postmenopausal women given its recently established effectiveness for reducing oxidative stress and improving vascular function in that population. Accordingly, the overall aim of this application is to assess the efficacy of a 12-week randomized controlled trial of moderate intensity AE training combined with oral MitoQ (20 mg/d) compared to AE+oral placebo (PL) or No AE+MitoQ on vascular vasodilatory function (brachial artery flow-mediated dilation; FMD) in healthy E2-deficient postmenopausal women. Insight into the causes for the improvement related to molecules (e.g., nitric oxide) that promote vasodilation, mitochondrial function, oxidative stress, and the influence of "circulating factors" will also be obtained. We hypothesize that AE+MitoQ will improve both FMD > AE+PL and > No AE+MitoQ, and that No AE+MitoQ will improve FMD > AE+PL. The greater improvements in endothelial function with AE+MitoQ vs. both AE+PL and No AE+MitoQ, and with No AE+MitoQ vs. AE+PL will be mediated by greater improvements in nitric oxide production, mitochondrial function, and mitochondrial and oxidative stress linked, at least in part, to changes in "circulating factors". The expected results from this study will establish the efficacy of MitoQ for restoring AE-vascular signaling in E2-deficient postmenopausal women and will provide the foundation for development of evidence-based guidelines for sex-specific AE programs for improving vascular health and preventing CVD in postmenopausal women.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 50 Years to 120 Years

Eligibility

Inclusion Criteria:

• resting blood pressure <140/90 mmHg;

• fasted glucose <126 mg/dL;

• sedentary/recreationally active (<2 days/wk vigorous exercise);

• healthy, as determined by medical history, physical examination, standard blood chemistries (chemistry panel, CBC and circulating thyroid levels) and ECG at rest and during exercise;

• nonsmokers;

• no use of medications that might influence cardiovascular function (i.e., antihypertensive, lipid lowering medications, blood thinners);

• no use of vitamin supplements or anti-inflammatory medications, or willing to stop 1 month prior to enrollment and for the duration of the study;

• no use of HT for at least 6 months;

• body mass index <40kg/m2.

Exclusion Criteria:

• Volunteers will be excluded from the study if they have contraindications to MitoQ or AE.

• acute liver disease, history of venous thromboembolic events, preexisting or active cardiac, renal or hepatic disease, history of stomach ulcer or bleeding or epilepsy or other seizure disorder;

• diabetes, active infection, disease that affects the nervous system,

• an abnormal resting ECG, angina and/or ECG evidence of acute myocardial ischemia during the exercise test (development of ST-segment depression of more than 0.3 mV that is either horizontal, down-sloping, or slowly upsloping -less than 1 mvolt/sec and lasts more than 0.08 sec; ST elevation; chest pain or discomfort), bundle branch blocks, A-V block greater than first degree, arrhythmias;

• chronic infections;

• thyroid dysfunction, defined as an ultrasensitive TSH <0.5 or >5.0 mU/L; volunteers with abnormal TSH values will be re-considered for participation in the study after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement;

• orthopedic or other problems that would interfere with participation in the exercise program

The volunteers who choose to participate will do so with the understanding that they will be randomly assigned to study groups that involve either AE+PL (33% chance), No AE+MitoQ (33% chance) or AE+MitoQ (33% chance).

Related Conditions & MeSH terms

• Aging
• Menopause

Intervention

Dietary Supplement:
• MitoQ
MitoQ is a biochemically modified form of ubiquinol
• Placebo
Each placebo capsule contains inert excipient and is identical in appearance

Behavioral:
• Aerobic exercise
Moderate intensity aerobic exercise on the treadmill

Locations

Country	Name	City	State
United States	University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research Laboratory	Aurora	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
University of Colorado, Denver	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change from baseline in Change in Suppression of endothelial function by mitochondrial oxidative stress at 10 weeks	Change in brachial artery flow-mediated dilation with acute supratherapeutic MitoQ dosed at 160mg	Baseline and 10 weeks
Other	Change from baseline in Serum exposure-induced endothelial cell reactive oxygen species production at 10 weeks	Endothelial cell whole-cell (CellROX) and mitochondria-specific (MitoSOX) reactive oxygen species levels after treatment with serum from subjects	Baseline and 10 weeks
Other	Change from baseline Serum exposure-induced endothelial cell nitric oxide production from at 10 weeks	Endothelial cell DAF-FM before and after addition of 200 µM Ach will quantify the capacity of HUVECs to generate nitric oxide after treatment with serum from subjects	Baseline and 10 weeks
Primary	Change from baseline Endothelial function at 10 weeks	Brachial artery flow-mediated dilation	Baseline and after 10 weeks